Aller au contenuAller au menuAller à la recherche

International Symposium on New Therapeutic Avenues in Parkinson’s Disease and Related Disorders, Bordeaux, France Organizers : Meissner, Tison and Bezard (registration, deadline April ,28th )

Abstract :


The overarching goal of the Symposia of the Bordeaux Neurosciences Institute is to bring locally a selected set of top researchers on a scientific topic that is of broad interest to the community. There will be 2-3 symposia per year, with each symposium lasting 1 or 2 days. Symposia are open to everyone from Bordeaux and outside, and are free."

 

The objective of this meeting is to brainstorm and dialogue between international Parkinson’s disease experts and representatives of leading healthcare companies and innovative biotech startups, to better understand the evolution of the therapeutic area (met versus unmet needs, clinical trial design, derisking translational development, emerging treatment challenges) and its strategic implications for the Healthcare industry.
The topics cover the most striking unmet treatment needs of our patients with the ambition to provide a cure for Parkinson’s disease in the future. Each expert will give an interactive presentation where he will briefly review his topic, define meaningful surrogate markers for the design of future clinical trials and identify the most promising and innovative treatment avenues

 Inscription fees vary from 0 to 150 euros according to your affiliation.


Wednesday - May 5, 2010

9:00-9:30 Opening ceremony

Manuel Tunon de Lara, President, University Victor Segalen Bordeaux 2
Chantal Lachenay-Llanas, Adjunct General Director, University Hospital Bordeaux
Jean-Marc Orgogozo, Chairman, Department of Clinical Neurosciences, University Hospital Bordeaux

Morning Session (9:30-13:00)
Chairmen
Pierre Burbaud & Emmanuel Cuny, Bordeaux, France

9:30-10:30
David Weiner, EMD Merck-Serono Inc, Rockland, MA, USA
Challenges in the development of Parkinson's disease therapeutics, an industry perspective

10:30-11:00 Break

11:00-12:00
Andres Lozano, Toronto, Canada
The potential of stereotactically-delivered treatments

12:00-13:00 Valerie Voon, Bethesda, MD, USA
Emerging treatment challenges, the dopamine dysregulation syndrome

13:00-14:00 Ibaïa café

Afternoon Session (14:00-16:30)
Chairmen
Wassilios Meissner, Bordeaux, France

14:00-15:00
Anthony Schapira, London, UK
How can we achieve neuroprotection in Parkinson’s disease: lessons from the past

15:00-16:00
Paola Piccini, London, UK
Advances in functional neuroimaging for Parkinson's disease

16:00-16:15
Erwan Bezard, Bordeaux, France
Presentation of the Bordeaux Institute for Neurodegenerative Disorders

16:15-16:45
Mark Frasier, Michael J Fox Foundation, New York, NY, USA
The Michael J Fox Foundation

 

Thursday - May 6, 2010

Morning Session (9:00-12:30)

Chairmen
Erwan Bezard, Bordeaux, France

9:00-10:00
Olivier Rascol, Toulouse, France
Design of future clinical trial

10:00-11:00
Wassilios Meissner, Bordeaux, France
How can we move on in atypical parkinsonism ?

11:00-11:30 Coffee Break

11:30-12:30
Christopher Goetz, Chicago, IL, USA
Future treatments for dyskinesia: lessons from the past

12:30-13:30 Lunch : Ibaïa café


Afternoon Session (13:30-17:30)

Chairmen: François Tison, Bordeaux, France

13:30-14:30
Thomas Gasser, Tübingen, Germany
Genetic dissection of Parkinson's disease as a basis for novel treatments ?

14:30-15:30
Jose Obeso, Pamplona, Spain
Unresolved problems in the treatment of Parkinson’s disease

15:30-16:00 Break

16:00-17:00
François Tison, Bordeaux, France
Parkinsonism and dementia: diagnosis and therapeutic challenges


17:00-17:30
Panel discussion: Conclusions from the Symposium
Jose Obeso, Wassilios Meissner and David Weiner

17:30 End of the Symposium